Schizophrenia Clinical Trials in Atlanta

View 58 new treatments for Schizophrenia in Atlanta, GA, and nearby areas, such as Sandy Springs. Every day, Power helps hundreds of schiz patients connect with leading medical research.
View 28 trials in Atlanta
Filter (28)

RL-007 for Cognitive Impairment in Schizophrenia

Recognify Life Sciences Clinic, Atlanta + 2 more

This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More

Verified

Recruiting
Phase 2
Est. 3 - 12 Weeks
Gary Walker, PhD
Study Director

Infliximab for Schizophrenia

Research Clinic, Atlanta + 2 more

This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per group) to patients with high inflammation. This study is important because schizophrenia can be a chronic and debilitating neuropsychiatric disorder and negative symptoms are some of the most difficult aspects of schizophrenia associated with worst functional outcomes. These symptoms do not typically respond to antipsychotic therapies, and as such, there are no current medications to treat negative symptoms.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
David R Goldsmith, MD
Principal Investigator

KarXT for Schizophrenia

Karuna Clinic, Atlanta + 3 more

This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Bruce Kinon, MD
Study Director

Lumateperone for Schizophrenia and Bipolar Disorder

Intra-Cellular Therapies Clinic, Atlanta + 3 more

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Adolescent Schizophrenia

Allergan Clinic, Atlanta + 2 more

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Recruiting
Phase 3
Est. 3 - 12 Weeks
Paul Yeung
Study Director

Long-term Safety of Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Atlanta + 2 more

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Brilaroxazine for Schizophrenia

Reviva Clinic, Decatur + 2 more

This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Director
Study Director

SEP-363856 for Schizophrenia

Sunovion Clinic, Atlanta + 2 more

This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
CNS Medical Director
Study Chair

KarXT for Schizophrenia

Karuna Clinic, Atlanta + 4 more

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director

KarXT for Schizophrenia

Karuna Clinic, Atlanta + 8 more

This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Page 1 of 3

Frequently Asked Questions

How much do schizophrenia clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do schizophrenia clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across schizophrenia trials in Atlanta, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for schizophrenia patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Atlanta is research being conducted for schizophrenia?

Prominent hospitals in Atlanta conducting schizophrenia clinical trials include Grady Memorial Hospital. Additionally, several trials are taking place in the northern area of the city, with approximately 8 trials ongoing as of 2024.

What promising new drugs are being tested?

In Atlanta, schizophrenia research is exploring treatments like Atypical Antipsychotics and NMDA Receptor Antagonists. Notable drugs being studied include Cariprazine, Valbenazine, and CVL-231.